A Two‐part, Single‐arm, Multicentre, Phase I Study of Zanubrutinib, a Selective Bruton Tyrosine Kinase Inhibitor, in Chinese Patients with Relapsed/refractory B‐cell Malignancies
British Journal of Haematology（2022）
Key words
B-cell malignancies,efficacy,phase I,safety,zanubrutinib
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined